KRAS and non-small cell lung carcinoma: Included in the cell lines tested by CRISPR are a panel of 26 esophageal cell lines, including KYSE-150, which has been reported to be sensitive to SMYD2 inhibition [11] and a panel of 18 KRAS mutant NSCLC cell lines that include the A549 cell line that has been reported to be sensitive to SMYD3 knockdown [21].